ESTRO 2024 - Abstract Book

S1954

Clinical - Mixed sites, palliation

ESTRO 2024

At baseline, the average global health status was 72, with discernible variations across different cancer types. Prostate cancer patients showed higher baseline QoL (averaging 78) compared to NSCLC, breast, or colorectal cancer patients with average values of 65, 68 and 70, respectively. Results of multiple linear regression showed a significant association of baseline QoL with the primary cancer type and performance status. Notably, patients with prostate cancer had better global health status compared to NSCLC, breast, and colorectal cancer patients (p<.0001). Additionally, patients with better WHO performance status (PS= 0) had better QoL (p=0.0002). During follow-up, global health status remained stable, with an average score of 72 and a standard deviation of 19. The distribution of global health status at baseline and first follow-up for the different cancer types are represented in Figure 1 .

The change in global health status from baseline to six months after SBRT was not significantly associated with any of the patient characteristics explored, including the number of oligometastases and concomitant treatment with systemic therapy. By using a 10-point difference threshold from baseline, 22% of patients reported a deterioration in their global health status, while 15.3% reported an improvement in their QoL. Notably, the percentage of patients with deterioration in QoL was 21.1%, 34.0%, 25.0%, and 17.4% in NSCLC, breast, colorectal and prostate cancer patients respectively, whereas 24.6%, 17.0%, 15.6% and 10.6% of NSCLC, breast, colorectal and prostate cancer patients respectively had an improvement in QoL.

Conclusion:

The study confirmed the feasibility of collecting QoL data in a prospective registry. Moreover, it revealed that QoL remained stable following metastases-directed SBRT in patients with oligometastatic breast, colorectal, lung, and prostate cancer.